Status:
RECRUITING
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
Lead Sponsor:
Singapore General Hospital
Collaborating Sponsors:
National Cancer Centre, Singapore
National Neuroscience Institute Singapore
Conditions:
Glioma, Malignant
Eligibility:
All Genders
21+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients...
Eligibility Criteria
Inclusion
- Men or Women, aged 21 years or older at time of screening
- Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
- With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
- Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
- Subject must consent to undergo all study procedures
Exclusion
- Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
- Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
- Proven cerebral metastases
- IDH-mutated gliomas
- Pregnancy/ breast-feeding
Key Trial Info
Start Date :
December 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06172595
Start Date
December 21 2023
End Date
February 28 2026
Last Update
December 3 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Centre Singapore
Singapore, Singapore
2
Singapore General Hospital
Singapore, Singapore